Drugs / Group A meningococcal polysaccharide vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06209398 | May 2018 → Dec 2024 | hand, foot and mouth disease | Jiangsu Province Centers for Disease Control and Prevention | Unknown | No outcome recorded |
| Phase 4 | NCT03274102 | Apr → Nov 2017 | hand, foot and mouth disease | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02601040 Comparator | Nov 2011 → Jun 2014 | hepatitis A virus infection | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Group A meningococcal polysaccharide vaccine | “Group A meningococcal polysaccharide vaccine (subcutaneous injection, 150ug) on day 30” NCT03274102 ↗ |
| Known as | MenA | “This study tested the hypothesis that the immunogenicity and safety of the simultaneous administration of enterovirus 71 (EV71) vaccine (dose 1) with recombinant hepatitis B...” PMID 30891604 ↗ Jul 2019 |
| Modality | Vaccine | “group A meningococcal polysaccharide vaccine (MenA)” PMID 30891604 ↗ Jul 2019 |
| Route | Intramuscular | “Group A Meningococcal Polysaccharide vaccine intramuscularly in the deltoid region.” NCT02601040 ↗ |